Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism

Endometriosis is a chronic, multifactorial, estrogen-dependent disease. The abnormal endocrine microenvironment of endometriosis lesions is considered a main feature and multiple enzymatic pathways leading to local increased synthesis of estrogens have been identified. However, the relevance of intracrinology in clinical practice is still lacking. Medline, Embase, Scopus database were systematically searched for studies reporting on local estrogens metabolism of endometriotic lesions. The main enzymatic pathways involved in the intracrinology of endometriosis such as aromatase (CYP19A1), 17β-hydroxysteroid dehydrogenase (HSD17B) type 1, type 2 and type 5, steroid sulfatase (STS), estrogen sulfotransferase (SULT1E1) were assessed with a critical perspective on their role in disease endocrine phenotyping, drug resistance and as therapeutic targets. Overall, studies heterogeneity and missing clinical data affect the interpretation of the clinical role of these enzymes. Although the use of some drugs such as aromatase inhibitors has been proposed in clinical practice for two decades, their potential clinical value is still under investigation as well as their modality of administration. A closer look at new, more realistic drug targets is provided and discussed. Altered expression of these key enzymes in the lesions have far reaching implication in the development of new drugs aimed at decreasing local estrogenic activity with a minimal effect on gonadal function; however, given the complexity of the evaluation of the expression of the enzymes, multiple aspects still remains to be clarified. Systematic Review Registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022311329, identifier CRD42022311329.

[1]  V. Gomel,et al.  Peritoneal fluid progesterone and progesterone resistance in superficial endometriosis lesions. , 2021, Human reproduction.

[2]  Ning Ma,et al.  Environmental Risk Factors for Endometriosis: An Umbrella Review of a Meta-Analysis of 354 Observational Studies With Over 5 Million Populations , 2021, Frontiers in Medicine.

[3]  P. Rogers,et al.  Superficial peritoneal endometriotic lesions are histologically diverse and rarely demonstrate menstrual cycle synchronicity with matched eutopic endometrium. , 2020, Human reproduction.

[4]  M. Selbach,et al.  mRNAs, proteins and the emerging principles of gene expression control , 2020, Nature Reviews Genetics.

[5]  R. Mamillapalli,et al.  Estrogen receptor-α immunoreactivity predicts symptom severity and pain recurrence in deep endometriosis. , 2020, Fertility and sterility.

[6]  F. Lenfant,et al.  Estrogen Receptors and Endometriosis , 2020, International journal of molecular sciences.

[7]  T. Penning,et al.  Aldo-keto reductase 1C3 - assessment as a new target for the treatment of endometriosis. , 2020, Pharmacological research.

[8]  J. Tille,et al.  Effect of local aromatase inhibition in endometriosis using a new chick embryo chorioallantoic membrane model , 2019, Journal of cellular and molecular medicine.

[9]  A. Romano,et al.  Local estrogen metabolism (intracrinology) in endometrial cancer: A systematic review , 2019, Molecular and Cellular Endocrinology.

[10]  J. Höchel,et al.  Absence of Drug‐Drug Interaction of Anastrozole on Levonorgestrel Delivered Simultaneously by an Intravaginal Ring: Results of a Phase 2 Trial , 2019, Journal of clinical pharmacology.

[11]  F. Labrie Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens from DHEA and their strictly local action and inactivation in peripheral tissues , 2019, Menopause.

[12]  D. Gibson,et al.  Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders , 2018, International journal of molecular sciences.

[13]  S. Xanthoulea,et al.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery , 2018, Front. Pharmacol..

[14]  Robert N. Taylor,et al.  Endometriosis , 2018, Nature Reviews Disease Primers.

[15]  Kazuto Ito,et al.  A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients , 2017, BMC Urology.

[16]  C. Becker,et al.  Reevaluating response and failure of medical treatment of endometriosis: a systematic review , 2017, Fertility and sterility.

[17]  N. Ács,et al.  Treatment of Endometriosis‐Associated Pain with Elagolix, an Oral GnRH Antagonist , 2017, The New England journal of medicine.

[18]  Mohamed Salah,et al.  First Dual Inhibitors of Steroid Sulfatase (STS) and 17β-Hydroxysteroid Dehydrogenase Type 1 (17β-HSD1): Designed Multiple Ligands as Novel Potential Therapeutics for Estrogen-Dependent Diseases. , 2017, Journal of medicinal chemistry.

[19]  M. Schultze-Mosgau,et al.  Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial. , 2016, Human reproduction.

[20]  R. Ferriani,et al.  Effects of steroid hormone on estrogen sulfotransferase and on steroid sulfatase expression in endometriosis tissue and stromal cells , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[21]  Vida Kocbek,et al.  Expression of AKR1B1, AKR1C3 and other genes of prostaglandin F2α biosynthesis and action in ovarian endometriosis tissue and in model cell lines. , 2015, Chemico-biological interactions.

[22]  Taisuke Mori,et al.  Dienogest reduces HSD17β1 expression and activity in endometriosis. , 2015, The Journal of endocrinology.

[23]  A. Genazzani,et al.  Neurobiology of DHEA and effects on sexuality, mood and cognition , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  P. Vercellini,et al.  Endometriosis: pathogenesis and treatment , 2014, Nature Reviews Endocrinology.

[25]  J. Gotteland,et al.  Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition , 2014, Reproductive sciences.

[26]  A. Prentice,et al.  ESHRE guideline: management of women with endometriosis. , 2014, Human reproduction.

[27]  J. Donnez,et al.  Differential expression of steroidogenic enzymes according to endometriosis type. , 2013, Fertility and sterility.

[28]  M. Daris,et al.  Identification of multiple and distinct defects in prostaglandin biosynthetic pathways in eutopic and ectopic endometrium of women with endometriosis. , 2013, Fertility and sterility.

[29]  S. Ferrero,et al.  Norethisterone acetate versus norethisterone acetate combined with letrozole for the treatment of ovarian endometriotic cysts: a patient preference study. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[30]  T. Rižner,et al.  Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis: A source of excessive hydroxy-estrogens and ROS? , 2013, Molecular and Cellular Endocrinology.

[31]  S. Ferrero,et al.  Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies , 2013, Archives of Gynecology and Obstetrics.

[32]  S. Bulun,et al.  Aromatase inhibitors for the treatment of endometriosis. , 2012, Fertility and sterility.

[33]  M. Poutanen,et al.  Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. , 2012, The Journal of clinical endocrinology and metabolism.

[34]  H. Maia,et al.  Correlation between aromatase expression in the eutopic endometrium of symptomatic patients and the presence of endometriosis , 2012, International journal of women's health.

[35]  Y. Shimizu,et al.  Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E₂ production in human endometriotic stromal cells in spheroid culture. , 2012, Fertility and sterility.

[36]  S. Alborzi,et al.  A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis , 2011, Archives of Gynecology and Obstetrics.

[37]  S. Ferrero,et al.  Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial , 2011, Reproductive biology and endocrinology : RB&E.

[38]  J. Donnez,et al.  Inhibition of steroid sulfatase decreases endometriosis in an in vivo murine model. , 2011, Human reproduction.

[39]  K. Vouk,et al.  Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. , 2011, Chemico-biological interactions.

[40]  D. Poirier Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: Key tools for studying and treating estrogen-dependent diseases , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[41]  T. Notsu,et al.  Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system , 2011, Steroids.

[42]  I. Sekine,et al.  Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. , 2010, Human reproduction.

[43]  G. Camerini,et al.  Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis. , 2009, Human reproduction.

[44]  J. Foidart,et al.  Absence of aromatase protein and mRNA expression in endometriosis. , 2009, Human reproduction.

[45]  B. Husen,et al.  Disturbed estrogen and progesterone action in ovarian endometriosis , 2009, Molecular and Cellular Endocrinology.

[46]  A. Romano,et al.  Increased production of 17beta-estradiol in endometriosis lesions is the result of impaired metabolism. , 2009, The Journal of clinical endocrinology and metabolism.

[47]  H. Tutill,et al.  Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. , 2008, Endocrine-related cancer.

[48]  J. Brosens,et al.  Inhibition of steroid sulphatase activity in endometriotic implants by 667 COUMATE: a potential new therapy. , 2007, Human reproduction.

[49]  R. Kamps,et al.  Estrogen metabolizing enzymes in endometrium and endometriosis. , 2007, Human reproduction.

[50]  E. Kubista,et al.  Expression of Aromatase and Estrogen Sulfotransferase in Eutopic and Ectopic Endometrium: Evidence for Unbalanced Estradiol Production in Endometriosis , 2007, Reproductive Sciences.

[51]  P. Acién,et al.  Aromatase expression in endometriotic tissues and its relationship to clinical and analytical findings. , 2007, Fertility and sterility.

[52]  B. Husen,et al.  Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[53]  R. Auchus,et al.  Deoxycorticosterone inactivation by AKR1C3 in human mineralocorticoid target tissues , 2006, Molecular and Cellular Endocrinology.

[54]  S. Matsuzaki,et al.  Analysis of aromatase and 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression in deep endometriosis and eutopic endometrium using laser capture microdissection. , 2006, Fertility and sterility.

[55]  L. Hefler,et al.  Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. , 2005, Fertility and sterility.

[56]  F. Ahsan,et al.  The vagina as a route for systemic drug delivery. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[57]  H. Sasaki,et al.  Gonadotropin-releasing hormone agonist inhibits estrone sulfatase expression of cystic endometriosis in the ovary. , 2004, Fertility and sterility.

[58]  J. Kitawaki,et al.  Gonadotropin-releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas. , 2003, Fertility and sterility.

[59]  Takashi Suzuki,et al.  Deficient 17β-Hydroxysteroid Dehydrogenase Type 2 Expression in Endometriosis: Failure to Metabolize 17β-Estradiol , 1998 .

[60]  H. Sasano,et al.  Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. , 1998, Fertility and sterility.

[61]  S. Bulun,et al.  Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. , 1997, The Journal of clinical endocrinology and metabolism.

[62]  S. Kennedy Endometriosis , 1992, The Lancet.

[63]  F. Labrie Intracrinology , 1991, Molecular and Cellular Endocrinology.

[64]  OUP accepted manuscript , 2021, Human Reproduction.

[65]  A. Romano,et al.  Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions. , 2014, The Journal of clinical endocrinology and metabolism.

[66]  A. Taherian,et al.  Effects of Letrozole Compared with Danazol on Patients with Confirmed Endometriosis: A Randomized Clinical Trial , 2010 .

[67]  S. Bulun,et al.  Aromatase and other steroidogenic genes in endometriosis: translational aspects. , 2006, Human reproduction update.

[68]  S. Soysal,et al.  The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. , 2004, Human reproduction.